Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

112 results about "Ester prodrug" patented technology

Ester prodrugs are normally designed to have simple ester groups, as they are expected to be cleaved and reactivated by a wide spectrum of cellular esterases. However, a number of pathogenic and commensal microbial esterases have been found...

P53-y220c selective small-molecular reactivator compound, pharmaceutical composition and use thereof

PCT designated stage expiredWO2025002177A1Organic active ingredientsOrganic chemistryDiseaseEster prodrug
Provided in the present invention are compounds shown as formula (I) and racemates, stereoisomers, tautomers, nitrogen oxides, solvates, polymorphs, metabolites, esters, prodrugs or pharmaceutically acceptable salts thereof, which have good p53-Y220C mutant activation effect, can be used for treating tumor diseases containing p53-Y220C mutant proteins, and can be used for preparing drugs for such disorders or diseases.
Owner:CHANGCHUN GENESCIENCE PHARM CO LTD

BRD4 protein degradation agent compound as well as preparation method and application thereof

The invention provides a compound as shown in a formula (I) and a racemate, a stereoisomer, a tautomer, an isotope label, a nitrogen oxide, a solvate, a polymorphic substance, a metabolite, ester, a prodrug or pharmaceutically acceptable salt thereof, which have better BRD4 inhibition and degradation effects as a drug, and can be used for preparing drugs related to BRD4 inhibition and degradation. And preventing and / or treating related diseases. # imgabs0 #
Owner:MIRACURE BIOTECHNOLOGY LTD

FGFR2 / 3 selective inhibitor, pharmaceutical composition and use thereof

Provided are a compound represented by formula (I) and a racemate, a stereoisomer, a tautomer, an isotope label, an oxynitride, a solvate, a polymorph, a metabolite, an ester, a prodrug, or a pharmaceutically acceptable salt thereof. The compound has a good FGFR2 / 3 inhibitory effect, and can be used for treating or preventing FGFR2 / 3-mediated disorders and diseases, and preparing drugs for treating or preventing such disorders and diseases.
Owner:CHANGCHUN GENESCIENCE PHARM CO LTD

Pyrazinamide compound as well as preparation method and application thereof

ActiveCN119143731Ahigh activitySuitable physical and chemical propertiesOrganic active ingredientsNervous disorderDiseaseEster prodrug
The invention discloses a pyrazinamide compound, which is a compound with a structure as shown in a general formula (I) or a tautomer, an enantiomer, a diastereomer, a racemate, a metabolite or a metabolic precursor of the compound, or pharmaceutically acceptable salt, ester and prodrug of the compound, or a hydrate of the compound, the invention also discloses a preparation method of the pyrazinamide compound and an application of the pyrazinamide compound in preparation of medicines for preventing and treating GPR52 related diseases. The invention also discloses a preparation method of the pyrazinamide compound and an application of the pyrazinamide compound in preparation of medicines for preventing and treating GPR52 related diseases.
Owner:OCEAN UNIV OF CHINA

Compounds for treatment of pain-related diseases

The invention provides a compound as shown in a formula I, or pharmaceutically acceptable salt or ester, prodrug, optical isomer, stereoisomer or solvate thereof. The compound disclosed by the invention can be used for preparing medicines for preventing or treating pain and related diseases thereof, so that a brand new material basis is laid for developing the pain and the related diseases thereof. # imgabs0 #
Owner:TAO PHARM SUZHOU CO LTD

Fibroblast growth factor receptor inhibitor, pharmaceutical composition and application thereof

The invention provides a compound as shown in a formula (I) and a racemate, a stereoisomer, a tautomer, an isotope label, nitrogen oxide, a solvate, a polymorphic substance, a metabolite, ester, a prodrug or pharmaceutically acceptable salt thereof. The compound has a good FGFR2 / 3 inhibition effect, can be used for treating or preventing FGFR2 / 3 mediated diseases and diseases, and can be used for preparing medicines for treating or preventing the diseases and diseases. # imgabs0 #
Owner:CHANGCHUN GENESCIENCE PHARM CO LTD

Fibroblast growth factor receptor inhibitor, pharmaceutical composition and use thereof

PCT designated stage expiredWO2025021033A1Organic active ingredientsOrganic chemistryDiseaseEster prodrug
A compound as shown in formula (I) and a racemate, a stereoisomer, a tautomer, an isotopic label, a nitrogen oxide, a solvate, a polymorph, a metabolite, an ester, a prodrug or a pharmaceutically acceptable salt thereof. Such a compound has a good inhibitory effect on FGFR2 and / or FGFR3, can be used for treating or preventing conditions and diseases mediated by FGFR2 and / or FGFR3, and can be used in the preparation of a drug for treating or preventing such conditions and diseases.
Owner:CHANGCHUN GENESCIENCE PHARM CO LTD

17 beta-HSD1 inhibitor compound, pharmaceutical composition and application of 17 beta-HSD1 inhibitor compound and pharmaceutical composition

The invention provides a compound as shown in a formula I, and a racemate, a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a polymorphic substance, a metabolite, an ester, a prodrug or a pharmaceutically acceptable salt thereof. The compound has a good 17 beta-HSD1 inhibition effect, can be used for treating or preventing 17 beta-HSD1 mediated diseases and diseases, and can be used for preparing medicines for treating or preventing the 17 beta-HSD1 mediated diseases and diseases. # imgabs0 #
Owner:CHANGCHUN GENESCIENCE PHARM CO LTD

NK cell membrane coated prodrug self-assembled nanoparticles as well as preparation method and application thereof

The invention discloses an NK cell membrane coated prodrug self-assembly nanoparticle as well as a preparation method and application thereof. The prodrug self-assembled nanoparticles are formed by self-assembling a bufalin carbonate prodrug and a paclitaxel carbonate prodrug independently or jointly through a nanoprecipitation method. The preparation method comprises the following steps: preparing bufalin carbonate prodrug, paclitaxel carbonate prodrug or double-prodrug self-assembled nanoparticles wrapped by an NK cell membrane, and further performing ultrasonic extrusion on the NK cell membrane, so that the nanoparticles are simple in preparation process and high in drug loading capacity. In-vitro cell experiments prove that the NK cell membrane can obviously improve the tumor cell uptake efficiency of the prodrug nanoparticles, enhance the anti-tumor effect of the prodrug nanoparticles, reduce acute toxicity and improve the administration safety, and can be further applied to clinical research in the future.
Owner:YANCHENG INST OF TECH +1

Indazole FGFR2 / 3 selective inhibitor, pharmaceutical composition and application thereof

The invention provides a compound as shown in a formula (I) and a racemate, a stereoisomer, a tautomer, an isotope label, nitrogen oxide, a solvate, a polymorphic substance, a metabolite, ester, a prodrug or pharmaceutically acceptable salt thereof. The compound has a good FGFR2 / 3 inhibition effect, can be used for treating or preventing FGFR2 / 3 mediated diseases and diseases, and can be used for preparing medicines for treating or preventing the diseases and diseases. # imgabs0 #
Owner:CHANGCHUN GENESCIENCE PHARM CO LTD

Derivative of rice bran extract as well as preparation method and application of derivative

The invention discloses a derivative of a rice bran extract as well as a preparation method and application of the derivative. A C-3 benzoate prodrug system is constructed, the transmembrane absorption efficiency is remarkably improved by optimizing the oil-water partition coefficient, fixed-point slow release of active ingredients is achieved through inflammatory tissue esterase, and high bioavailability and low irritation are both considered. Meanwhile, C-25 fluorine atoms are introduced to serve as biological electron isosteres, and target affinity is enhanced by means of the unique electronic effect and polar hydrophobicity of the C-25 fluorine atoms; spatial conformation is locked through side chain saturation, so that the compound shows anti-inflammatory and tissue repair activity which is obviously superior to that of natural cycloartanol under the same dosage.
Owner:BOHAI UNIV

Combination comprising capivasertib and abiraterone for treating PTEN-deficient metastatic hormone-sensitive prostate cancer (MHSPC)

The present disclosure relates to methods of treating PTEN-deficient metastatic hormone- sensitive prostate cancer (mHSPC) in patients in need thereof, the methods comprising administering to the patients a combination comprising capivasertib or a pharmaceutically acceptable salt thereof; and abiraterone or an ester prodrug thereof, or a pharmaceutically acceptable salt thereof.
Owner:ASTRAZENECA AB

A PAK4 kinase inhibitor, its preparation method and uses

This invention discloses a compound of formula I, or a pharmaceutically acceptable salt, stereoisomer, ester, prodrug, or solvate thereof. Experimental results show that the compound provided by this invention exhibits high inhibitory activity against PAK4 kinase and PAK I / II selectivity, good liver microsomal stability, and rat PK pharmacokinetic properties, especially with low hERG cardiotoxicity risk, representing a significant improvement over prior art compounds.
Owner:CHENGDU HYPERWAY PHARM CO LTD +1

sGC STIMULATORS

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts, pharmaceutical formulations comprising them as well as their phosphate ester prodrugs, and their uses alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and / or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or the upregulation of the NO pathway is desirable. The compounds are of Formula I
Owner:TISENTO THERAPEUTICS INC

Antihypertensive polyol compound and derivative thereof

The present invention provides a compound as represented by formula I, or a pharmaceutically acceptable salt or ester, a prodrug, an optical isomer, a stereoisomer, or a solvate thereof. The compound provided by the present invention can be used for preparing drugs for preventing or treating hypertension, or hypertension-related diseases, or pulmonary hypertension, or pulmonary hypertension-related diseases. The compound provided by the present invention has a different mechanism from existing drugs for treating hypertension and pulmonary hypertension, thereby laying a new material foundation for the development of drugs for treating hypertension and pulmonary hypertension.
Owner:TAO PHARM SUZHOU CO LTD

17β-HSD1 inhibitor compounds, pharmaceutical composition and use thereof

Provided in the present invention are compounds represented by formula (I) and racemates, stereoisomers, tautomers, nitrogen oxides, solvates, polymorphs, metabolites, esters, prodrugs, or pharmaceutically acceptable salts thereof. The compounds have good 17β-HSD1 inhibition effect, can be used for treating or preventing 17β-HSD1-mediated disorders and diseases, and can be used for preparing drugs for treating or preventing such disorders and diseases.
Owner:CHANGCHUN GENESCIENCE PHARM CO LTD

N-oxalyl-D-phenylalanine compounds and ester prodrugs thereof, preparation methods, pharmaceutical compositions and applications

The present invention discloses a N-oxalyl-D-phenylalanine compound and its ester prodrug, preparation method, pharmaceutical composition and application, wherein the N-oxalyl-D-phenylalanine compound is shown in the general formula (I). The present invention provides a series of highly selective and highly active FIH small molecule inhibitors and their prodrugs, which can selectively inhibit FIH activity and effectively reduce triglyceride content at the cellular and animal levels, and can be used to improve fat metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, and non-alcoholic fatty hepatitis. In addition, such FIH small molecule inhibitors are also expected to provide a molecular basis for the study of FIH molecular mechanism and pharmacological function, and to assist in the study of hypoxia response pathway regulation.
Owner:CHINA PHARM UNIV

Nucleoside antiviral prodrugs capable of being efficiently released by lung tissues as well as preparation method and application of nucleoside antiviral prodrugs

The invention discloses a nucleoside antiviral NHC diester prodrug as shown in a formula I and pharmaceutically acceptable salts thereof, and a preparation method and medical application of the nucleoside antiviral NHC diester prodrug. Pharmacological experiments prove that the compound disclosed by the invention has relatively strong inhibitory activity on replication of multiple RNA viruses. Particularly, the compound has good lung microsome release efficiency, the species difference of the lung release efficiency is small, the consistency of the in-vivo drug effect of the antiviral drug and the in-vivo drug effect of the antiviral drug can be improved, and the risk of species difference of prodrug release antiviral active ingredients is avoided. Therefore, the compound provided by the invention has good broad-spectrum antiviral activity, and can be used as a broad-spectrum antiviral drug for treating various respiratory virus infections.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

Indolinespirocyclic derivatives, process for their preparation and their use in medicine

Disclosed are a compound shown in formula I and racemate, stereoisomer, tautomer, isotopically labeled, nitroxide, solvate, polymorph, metabolite, ester, prodrug or pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same, a preparation method thereof, and a use thereof as a GHSR agonist in the preparation of a drug for the diagnosis, prevention and / or treatment of growth hormone-dependent diseases, the structure of formula I is as follows:
Owner:CHANGCHUN GENESCIENCE PHARM CO LTD

Tumor redox activated 6-thiopurine containing dimer compounds

Disclosed herein are 6-thiopurine containing dimer compounds of Formula I: or a pharmaceutically acceptable salt, ester, prodrug, hydrate or tautomer thereof wherein two R1 are simultaneously H or (PO3) 2-and two R2 are simultaneously H or OH. Also disclosed is a process for preparing a compound of formula I from the corresponding 6-thiopurine-containing monomeric compound. Also disclosed is a process for converting a dimeric compound of Formula I to the corresponding 6-thiopurine-containing monomeric compound. The compounds can be used for treating, ameliorating or preventing various types of cancers, in particular cancers with drug resistance. The compounds of formula I may also be used in various ways in combination with checkpoint inhibitors and / or radiation to treat various types of cancer. # imgabs0 #
Owner:MAIA BIOTECHNOLOGY INC

P53-Y220C selective small-molecule reactivator compound, pharmaceutical composition and application of p53-Y220C selective small-molecule reactivator compound

The invention provides a compound as shown in a formula (I) and a racemate, a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a polymorphic substance, a metabolite, an ester, a prodrug or a pharmaceutically acceptable salt thereof, and the compound has a good p53-Y220C mutant activation effect and can be used for treating tumor diseases containing p53-Y220C mutant protein. And preparation of medicaments for such conditions or diseases.
Owner:CHANGCHUN GENESCIENCE PHARM CO LTD

Use of HPK1 inhibitor in prevention and / or treatment of human pathogen infection

Provided in the present invention are the uses of an HPK1 inhibitor in preparation of drugs for preventing and / or treating human diseases or symptoms caused by pathogen infection or related to pathogen infection, and in preparation of drugs for preventing and / or treating tumors. The HPK1 inhibitor is a compound represented by following general formula I, or pharmaceutically acceptable salts, stereoisomers, esters, prodrugs, solvates and deuterated compounds thereof .
Owner:GUANGZHOU YUFAN NANTU BIOTECHNOLOGIES CO LTD

Polyol derivative for antagonizing and inhibiting TRPV4-rhoa target and use thereof

PCT designated stageWO2025218674A1Senses disorderNervous disorderDiseaseEster prodrug
Disclosed in the present invention are a compound represented by formula I, or a pharmaceutically acceptable salt thereof or an ester thereof, a prodrug thereof, an optical isomer thereof, a stereoisomer thereof, or a solvate thereof as an antagonist or an inhibitor for antagonizing and inhibiting a TRPV4-RhoA target, and use thereof in treating TRPV4-RhoA target-related diseases. The class of compounds exhibits an excellent effect of antagonizing TRPV4 and inhibiting RhoA activity, thereby laying a brand-new substance foundation for developing drugs for treating TRPV4-RhoA target-related diseases.
Owner:TAO PHARM SUZHOU CO LTD

PROTAC targeting Bcl-xL protein and application thereof

The invention relates to PROTAC (Protein Protein Activator) targeting Bcl-xL protein and an application of the PROTAC. Specifically, the invention provides a compound of formula I or a pharmaceutically acceptable salt, ester, prodrug, solvate, stereoisomer or deuterated compound thereof: A-L-E (I) wherein A is a small molecule ligand part targeting Bcl-xL protein; e is a small molecule ligand part of a targeted E3 ubiquitin ligase complex; l is a linking group. The compounds or compositions of the present invention may be used to selectively kill one or more senescence cells or to treat senescence-related diseases or conditions in a subject.
Owner:BEIJING SUNCELL BIO-MEDICAL CO LTD

FGFR2 / 3 selective inhibitor, pharmaceutical composition and application thereof

Provided are a compound represented by formula (I), and a racemate, a stereoisomer, a tautomer, an isotope label, a nitrogen oxide, a solvate, a polymorphic substance, a metabolite, an ester, a prodrug or a pharmaceutically acceptable salt thereof. The compound has a good FGFR2 / 3 inhibition effect, can be used for treating or preventing FGFR2 / 3 mediated diseases and diseases, and can be used for preparing medicines for treating or preventing the diseases and diseases.
Owner:CHANGCHUN GENESCIENCE PHARM CO LTD

Amino-acid ester prodrug of peramivir as well as preparation method and application of amino-acid ester prodrug

The invention relates to an amino-acid ester prodrug of peramivir, which has the following structural formula: in the formula, R is L-valine, D-valine and L-isoleucine taking 2, 3-butanediol as a connecting arm, and L-isoleucine, L-alanine, L-valine or D-valine taking 2-methyl-1, 3-propylene glycol as a connecting arm. Mouse in-vivo pharmacokinetic verification shows that the amino-acid ester prodrug of the peramivir has remarkably higher absolute bioavailability and is suitable for being prepared into an oral administration preparation.
Owner:JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE

Compounds for treating or preventing respiratory syncytial virus diseases

The invention belongs to the field of anti-infective drugs, discloses a compound for treating or preventing respiratory syncytial virus diseases, and provides compounds as shown in formulas (I-1) and (I-2) and pharmaceutically acceptable salts, esters, prodrugs, solvates, isomers or isotope forms thereof, the compound disclosed by the invention has antiviral activity and can be used for preparing a medicine for treating or preventing in-vivo virus infection of a subject susceptible to virus infection or experiencing virus infection.
Owner:WUHAN WUYAO SCI & TECH CO LTD +1

sGC STIMULATORS

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts, pharmaceutical formulations comprising them as well as their phosphate ester prodrugs, and their uses alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and / or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or the upregulation of the NO pathway is desirable. The compounds are of Formula I
Owner:TISENTO THERAPEUTICS INC

17β-HSD1 inhibitor compounds, pharmaceutical composition and use thereof

Provided in the present invention are compounds represented by formula (I) and racemates, stereoisomers, tautomers, nitrogen oxides, solvates, polymorphs, metabolites, esters, prodrugs, or pharmaceutically acceptable salts thereof. The compounds have good 17β-HSD1 inhibition effect, can be used for treating or preventing 17β-HSD1-mediated disorders and diseases, and can be used for preparing drugs for treating or preventing such disorders and diseases.
Owner:CHANGCHUN GENESCIENCE PHARM CO LTD

Preparation method of chiral phthaloyl ester prodrug

The invention discloses a preparation method of a chiral phthaloyl ester prodrug, and relates to the technical field of organic chemical synthesis. According to the invention, isothiourea is taken as a Lewis base catalyst, acyl chloride is taken as an acylating agent, and an acylation dynamic kinetic resolution process of racemic 3-hydroxyisobenzofuran-1 (3H)-ketone (hereinafter referred to as phthalide) is realized, so that chiral phthaloyl ester with good to excellent yield and enantioselectivity and a natural product and a medicine containing the structure are formed.
Owner:GUIZHOU UNIV